WallStreetZenWallStreetZen

NASDAQ: RNAC
Cartesian Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for RNAC

Based on 4 analysts offering 12 month price targets for Cartesian Therapeutics Inc.
Min Forecast
$1.00+36.99%
Avg Forecast
$3.25+345.21%
Max Forecast
$5.00+584.93%

Should I buy or sell RNAC stock?

Based on 4 analysts offering ratings for Cartesian Therapeutics Inc.
Buy
Strong Buy
1 analysts 25%
Buy
2 analysts 50%
Hold
1 analysts 25%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RNAC stock forecasts and price targets.

RNAC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-08-18
lockedlocked$00.00+00.00%2023-08-18
lockedlocked$00.00+00.00%2023-08-18
lockedlocked$00.00+00.00%2023-08-18

1 of 1

Forecast return on equity

Is RNAC forecast to generate an efficient return?
Company
N/A
Industry
-0.69%
Market
30.34%

Forecast return on assets

Is RNAC forecast to generate an efficient return on assets?
Company
N/A
Industry
-0.29%

RNAC revenue forecast

What is RNAC's revenue in the next 2 years based on estimates from 2 analysts?
Avg 1 year Forecast
$30.5M-11.55%
Avg 2 year Forecast
$61.6M+78.24%
RNAC's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RNAC revenue growth forecast

How is RNAC forecast to perform vs Biotechnology companies and vs the US market?
Company
44.09%
Industry
34.65%
Market
7.68%
RNAC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RNAC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RNAC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RNAC$0.73$3.25+345.21%Buy
GBIO$1.71$10.67+523.80%Buy
CAPR$3.69$40.00+984.01%Buy
ENGN$7.25N/AN/A
ACRV$5.03$23.50+367.20%Strong Buy
View Top Biotech Stocks

Cartesian Therapeutics Stock Forecast FAQ

Is Cartesian Therapeutics Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: RNAC) stock is to Buy RNAC stock.

Out of 4 analysts, 1 (25%) are recommending RNAC as a Strong Buy, 2 (50%) are recommending RNAC as a Buy, 1 (25%) are recommending RNAC as a Hold, 0 (0%) are recommending RNAC as a Sell, and 0 (0%) are recommending RNAC as a Strong Sell.

If you're new to stock investing, here's how to buy Cartesian Therapeutics stock.

What is RNAC's revenue growth forecast for 2023-2024?

(NASDAQ: RNAC) Cartesian Therapeutics's forecast annual revenue growth rate of 44.09% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.65%, and it is also forecast to beat the US market's average forecast revenue growth rate of 7.68%.

Cartesian Therapeutics's revenue in 2023 is $34,533,000.On average, 2 Wall Street analysts forecast RNAC's revenue for 2023 to be $4,740,401,331, with the lowest RNAC revenue forecast at $3,334,872,259, and the highest RNAC revenue forecast at $6,146,085,607.

In 2024, RNAC is forecast to generate $9,552,817,402 in revenue, with the lowest revenue forecast at $3,104,083,640 and the highest revenue forecast at $16,001,551,164.

What is RNAC's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: RNAC) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.29%.

What is RNAC's Price Target?

According to 4 Wall Street analysts that have issued a 1 year RNAC price target, the average RNAC price target is $3.25, with the highest RNAC stock price forecast at $5.00 and the lowest RNAC stock price forecast at $1.00.

On average, Wall Street analysts predict that Cartesian Therapeutics's share price could reach $3.25 by Aug 18, 2024. The average Cartesian Therapeutics stock price prediction forecasts a potential upside of 345.21% from the current RNAC share price of $0.73.

What is RNAC's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: RNAC) forecast ROE is N/A, which is considered weak.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.